Introduction

CD4
+ CD127 low CD25 + regulatory T cells (Tregs), the majority of which differentiate in, and egress from, the thymus are an immune subset with a critical role in the maintenance of self-tolerance and protection against tissue damage and autoimmunity [1] . This Treg subset is defined by the expression of the transcription factor FOXP3, which is essential for their differentiation, maintenance and function [2] . The stable FOXP3 expression that is required for Treg function depends on demethylation of a sequence in the first intron of the gene, termed the Treg-specific demethylated region (TSDR) [3] . FOXP3, along with other transcription factors, suppresses the expression of the IL-2 gene in these Tregs [2, 4] , making them critically dependent on IL-2 production from conventional or effector T cells (Teffs). For example, reduction of IL-2 in the pancreatic islets leads to a loss of FOXP3 expression and Treg numbers in a mouse model of autoimmune type 1 diabetes (T1D) [5, 6] . Furthermore, in humans, variation of genes in the IL-2 pathway, for example IL2RA encoding CD25, alters susceptibility to autoimmune diseases, including T1D [7] [8] [9] [10] . The leading diseaseassociated variant of IL2RA is correlated with reduced expression of CD25, leading to a decrease in Treg IL-2 sensitivity and suppressive ability [11, 12] . These findings have provided the rationale for clinical studies aiming at expanding Tregs in vitro, or increasing Treg numbers and fitness in vivo by IL-2 administration, for the treatment of autoimmune diseases [13] [14] [15] . However, there is growing evidence of heterogeneity and plasticity among Tregs [16] [17] [18] . A population of FOXP3 + Tregs has been identified in humans that constitutively expresses the Th17 lineagespecific transcription factor RORγt, a portion of which produce IL-17 upon in vitro activation [19] [20] [21] [22] . More recently, two studies have demonstrated that the frequency of mouse RORγt + FOXP3 + Th17 Tregs in the colon is determined by the composition of the intestinal commensal microbiota [23, 24] . These data indicate that Th17 Tregs play a key role in the regulation of the intestinal Th17 immune responses to commensal and pathogenic bacteria, while preventing inflammation. Consistent with this hypothesis, adoptive transfer of RORγt + FOXP3 + Th17 Tregs completely abrogated the development of inflammation in a mouse colitis model, and displayed increased suppressive capacity in vivo compared to conventional RORγt − FOXP3 + Tregs [25] . Further supporting Clinical Immunology 179 (2017) [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] the suppressive function of these cells in vivo, another study also showed that a subset of FOXP3 int RORγt + Tregs were able to prevent the development of autoimmune diabetes in the NOD model [26] . The mutually opposing regulatory functions of the FOXP3 and RORγt transcription factors have raised questions regarding the origin and differentiation of Th17 Tregs, leading to the hypothesis that Th17 T effector cells (Teff) and Tregs could share a similar differentiation pathway, and have been selected to ensure immunity at the barrier surfaces and the adaptation of the host to commensal bacteria [27] . IL-6, which is a potent driver of inflammatory disease, is instrumental for the commitment to the Th17 lineage, by inhibiting FOXP3-mediated suppression of RORγt, thereby promoting the differentiation of the Th17 Teff lineage in mice [28] [29] [30] . In addition, studies in mice have also shown that IL-6 signalling is an established factor to inhibit the suppressive function of Tregs [31] , although this effect has been shown to be Treg extrinsic, through the activation of Teffs, which are able to escape Treg suppression [32] . Furthermore, in the presence of IL-6, Tregs have been reported to induce IL-17 production by Th17 Teffs cells and have been shown to be themselves capable of producing IL-17 [33] .
The effects of IL-6 in studies of human CD4 + T cells differ from those reported using cells from mice in several aspects. For example, IL-6 does not contribute to the differentiation of naïve CD4 + T cells to the Th17 lineage as it can in mice, although IL-1β and IL-6 together induce IL-17A secretion from human memory CD4 + Th17 cells [34] . Furthermore, the exact role of IL-6 signalling on human Treg function remains uncertain. In psoriasis patients, elevated IL-6 production in affected skin has been suggested to promote the differentiation of IL-17-producing pathogenic Th17 cells and reduce the suppressive capacity of Tregs, although this latter effect is likely to be indirect [35] . Evidence from Bhela et al. also supports the hypothesis that Tregs are not the direct target of IL-6 for its ability to elicit resistance to Treg-mediated suppression [36] . In contrast, Bending et al. have reported that IL-6 provides proregulatory signals directly to human Tregs [37] . Previously, a genetic variant in IL6R (rs2228145 A NC; Asp358Ala) has been associated with human inflammatory diseases, including T1D [38] , ankylosing spondylitis [39] and rheumatoid arthritis [40] , presumably due to a greater expression of the IL-6 receptor and therefore a higher IL-6 signalling capacity in CD4 + Teffs expressing the common Asp358 susceptibility allele compared to Ala358 [38] . Furthermore, IL-6 signalling is increased in T1D patients owing to increased IL-6R expression [41] . These results indicate that inhibition of IL-6 signalling could be a therapeutic approach in T1D, as it is in other human inflammatory diseases [42, 43] . Nevertheless, blockade of IL-6, which is a key pathway in immune defence, could raise the risk of serious infections in T1D patients and hence targeting the therapy to a specific cell type could offer advantages in therapy. In the current study we show that a portion of the memory IL-6R hi CD127 Tregs will be highly sensitive to the endogenous production of IL-2 induced by infection or inflammation, thereby stimulating the recruitment of these highly suppressive Tregs, which we suggest could be normally resident in the intestine and mesenteric lymph nodes, to sites of infected cells or inflammation, where these Tregs curtail effector activities and prevent potentially pathogenic tissue damage. However, in the presence of high tissue concentrations of IL-6 these cells might lose their suppressive capacity temporarily to help fight infection, an effect that would not be advantageous in a site of chronic inflammation in which a pathogen was not present. With the combination of surface markers we have defined here, these cells can now be purified from whole blood and biopsy tissues to further study their functions and their putative immunotherapeutic properties.
Materials and methods
Subjects and study design
Patient selection and the protocol for the "Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes" (DILT1D) has been published previously [15, 44] . A subset of 22 T1D patients (median age = 26, range 18-48) were selected for this study, and assessed for the expression of IL-6R on Tregs. A blood sample was taken before treatment to establish baseline Treg frequencies and phenotypes, followed by subcutaneous administration of a single dose of recombinant human IL-2 (Proleukin/ aldesleukin; dose range 45,000-737,000 IU/m 2 ) on day 0. The patients were bled 90 min after treatment, and then daily to day 4 and at days 7, 9, 14, 21 and 60. The DILT1D data from individuals prior to normalisation as a group are available, however they cannot be anonymised sufficiently to be able to put into the public domain without risk of participant identification. Data are available on request, through the Cambridge University institutional repository (DOI link: https://doi. org/10.17863/CAM.832).
Study participants for all further immunophenotyping and functional assays included in this study were adult healthy volunteers recruited from the Cambridge BioResource (http://www.cambridgebioresource. org.uk/). All samples were collected after approval from the relevant research ethics committees, and written informed consent was obtained from the participants.
Flow cytometry
For the clinical trial participants, 30 ml whole blood were collected into lithium heparin tubes and processed within 4 h of phlebotomy. Immunostaining was performed in whole blood with specific fluorochrome-conjugated antibodies (Table 1 in Ref. [45] ) at room temperature for 45 min. IL-6R expression was assessed using a phycoerythrin (PE)-conjugated antibody, which provided the better resolution in our flow cytometric setting. This was critical to increase the sensitivity of the assay, and assess quantitative differences in IL-6R expression in different T cell subsets.
Treg immunophenotyping in healthy donors was performed in fresh peripheral blood mononuclear cells (PBMCs) isolated by Ficoll gradient centrifugation (Lymphoprep; STEMCELL Technologies) from whole blood within 2 h of phlebotomy. Cells were stained with fluorochrome-conjugated antibodies against surface receptors ( Table 1 in Ref. [45] ) for 45 min at 4°C. Fixation and permeabilisation was performed using FOXP3 Fix/Perm Buffer Set (BioLegend) and cells were then stained with the respective intracellular antibodies for 45 min at room temperature ( Table 1 in Ref. [45] ).
Cytokine secretion assays
To assess cytokine production, CD4 + T cells were isolated from whole blood by negative selection using RosetteSep (STEMCELL Technologies) within 2 h of phlebotomy. Cells were resuspended in X-Vivo15 (Lonza) + 5% heat-inactivated, filtered human AB serum (Sigma), and cultured (1-2 × 10 6 CD4s/well) in a 24-well flat-bottom cell culture plate (CELLSTAR, Greiner) at 37°C in the presence or absence of the 1 × Cell Stimulation Cocktail (eBiosiences), containing phorbol myristate acetate (PMA), ionomycin, and protein transport inhibitors (brefeldin A and monensin). After 6 h culture, cells were harvested and immunostained with surface and intracellular antibodies ( Table 1 in Ref. [45] ). The unstimulated cells were used to determine background levels of cytokine production. Dead-cell exclusion was performed using the eFluor780 Fixable Viability Dye (eBiosciences).
Intracellular pSTAT3 immunostainings
PBMCs were isolated from three healthy donors by Ficoll gradient centrifugation from whole blood within 2 h of phlebotomy. IL-6 sensitivity of the memory Treg and Teff subsets was determined by intracellular pSTAT3 immunostaining in freshly isolated PBMCs in response to IL-6 stimulation in vitro, as previously described [38] .
Cell sorting
Cell sorting was performed using a BD FACSAria Fusion flow cytometer (BD Biosciences) after pre-enrichment of CD4 + T cells from whole blood by negative selection. Fluorescence-conjugated antibodies used for sorting are described in Table 1 in Ref. [45] . Sorting efficiencies were determined in four donors, based on IL-6R and TIGIT expression and ranged between 90 and 99%.
FOXP3 and CTLA4 demethylation assays
Epigenetic profiling of the FOXP3 TSDR and the CTLA-4 gene was performed using a next-generation sequencing method described previously [46] . DNA was extracted from flow sorted cells from three independent healthy male donors (containing a single copy of the FOXP3 gene on chromosome X) and bisulfite treated using Epitect fast lyse all kit (Qiagen For the proliferation assays, sorted cells were labelled with eFluor450 Cell Proliferation Dye, and cultured in the presence of exogenous IL-2 (100 U/ml; Proleukin) and α-CD3/CD28 activation beads, at a 1:1 bead:Teff ratio.
Proliferation and suppressive capacity were calculated using the Division Index (DI) in FlowJo (Tree Star), setting 0% suppression as the condition with the respective Teffs cultured in the absence of Tregs. The DI represents the average number of cell divisions that each seeding Teff cell has undergone and was obtained using the following equation: DI = Total number of Cell Divisions/Initial number of Teff cells in 
Transcriptional profiling of the Treg subsets
Gene expression profiling was performed by NanoString, using the pre-designed nCounter Human Immunology v2 Panel (NanoString Technologies). The four assessed immune cell subsets were flow sorted as described above, and 25,000 cells were collected into RLT lysis buffer (Qiagen) either: (i) directly ex vivo; or (ii) following in vitro stimulation for 165 min in the presence or absence of 50 ng/ml PMA (Sigma-Aldrich) and 500 ng/ml ionomycin (Sigma-Aldrich), without addition of protein transport inhibitors. RNA from the flow-sorted T cell subsets was extracted using the RNAeasy Micro Plus kit (Qiagen), with gDNA cleanup, following manufacturer's instructions. Total RNA samples were then hybridised to the NanoString CodeSets, following manufacturer's instructions. Expression levels were assessed using an nCounter Flex instrument (NanoString Technologies). Data were processed using the nSolver Analysis Software following normalisation of the raw read counts to the geometric mean of positive control spikeins, and the gene expression of 15 selected housekeeping genes (ATG10, C14orf166, CD3E, CD46, G6PD, GPI, POLR1B, POLR2A, PSMB5, PSMB10, PTPRC, SDHA, SKI, TOLLIP and TUBB) that were found to have low variability on both the samples collected ex vivo and following in vitro stimulation.
Statistical analyses
Statistical analyses were performed using Prism software (GraphPad) and R (www.r-project.org.com). Statistical significance was assessed using a two-tailed non-parametric Mann-Whitney test.
Comparison of immune phenotypes between the assessed Treg subsets from the same individual was performed using a two-tailed paired nonparametric Wilcoxon signed rank test.
Differential expression of normalised NanoString transcriptional data was calculated using a paired analysis with DESeq2 v1.12.3 [47] , with pre-set size factors equal to one for all samples. Adjusted P values correspond to the false discovery rates (FDR) for differential expression, computed after correcting P values for multiple testing. A missing FDR is reported for genes that were found to contain an expression outlier by DESeq2 Cook's distance-based flagging of P values, and thus excluded from multiple testing.
Results
Frequency of IL-6R
hi Tregs is transiently increased by a single dose of
IL-2 in vivo
To (Fig. 1C) , and was consistent with the expansion of total CD4 + CD127 low CD25 + Tregs reported previously [15] . The IL-2-induced increase in IL-6R hi Treg frequency was sustained for up to three days after treatment in patients receiving the higher doses (Fig. 1A) , before returning to the pre-treatment or baseline frequencies. group. P values for the maximum increase in the frequency of the assessed parameter in response to a single dose of IL-2 was calculated using a two-tailed paired non-parametric Wilcoxon signed rank test comparing the frequencies observed at the timepoint where the maximal increase was achieved with the respective baseline pre-treatment frequencies. P values for the IL-2 dose-dependent effects were calculated using a two-tailed non-parametric Mann-Whitney test comparing the frequency of IL-6R hi cells between the two dose groups at each timepoint. *P b 0.05; **P b 0.01; ns = not significant.
marker PD-1 (20.6% versus 10.4%, P = 1.2 × 10 −7
; Fig. 2C (Fig. 2D ).
Stratification of the IL-6R
hi Treg subset by TIGIT expression
To address the heterogeneity in IL-6R hi mTregs, we stratified this subset based on the expression of the surface-expressed co-inhibitory receptor TIGIT (Fig. 3A) . We observed a differential expression of IL-6R between the two TIGIT-defined mTreg subsets, with an increased fre Fig. 3C ) and still markedly higher than memory Teffs (Fig. 3B,C) . In addition, IL-6R hi TIGIT − mTregs were found to be almost completely positive for CTLA-4 (90.9%), which is a key mediator of Treg suppressive function. This frequency was higher than IL-6R hi TIGIT + mTregs (80.3%, P = 2.7 × 10 − 5 ) and particularly pronounced when compared to the IL-6R lo TIGIT + subset (58.6%, P = 1.9 × 10 − 6 ; Fig. 3C Fig. 3B ). The remainder were methylated at FOXP3, which is in contrast with the other two conventional Treg subsets, in which nearly all of the cells (N92%) were demethylated at the FOXP3 TSDR (Fig. 4B) . The IL-6R hi TIGIT − Treg population also showed 90.6% demethylation of a sequence in exon 2 of CTLA4 (Fig. 4B) we assessed the mRNA expression of 579 immune genes in sorted cells from nine healthy donors (Table 2 in Ref. [45] ). The expression of TIGIT and IL-6R was assessed post-sorting and displayed a distinct expression in the respective subsets, indicating a very high level of purity (Fig. 1D in Ref. [45] ). We found that ex vivo IL-6R hi TIGIT − mTregs showed a distinct Th17 transcriptional signature (Fig. 5A) , marked by the specific higher expression of the Th17 lineage discrimination transcription factor RORγt (encoded by RORC). The observed Th17 signature was also defined by higher expression of additional Th17 genes, including KLRB1 (CD161), CCR6, IL1R1 and IKZF3 (AIOLOS) [48] [49] [50] [51] , in IL-6R hi TIGIT − mTregs (Fig. 5A,B Furthermore, we also noted the increased expression of LAG3 and IL10 (Fig. 5C ), which have been described as markers of the IL-10-producing FOXP3 − Tr1 subset [52, 53] , and could also account for a proportion of the cells with a methylated FOXP3 TSDR and a lack of FOXP3 expression in this population. Conversely, we found that the expression of two transcription factors, LEF1 and TCF7 (encoding TCF1), previously shown to co-ordinately repress the Th17 transcriptional program [54, 55] , were specifically downregulated in IL-6R hi TIGIT − mTregs (Fig. 5D ). These data demonstrate a strong transcriptional commitment of IL-6R hi TIGIT − mTregs to the Th17 phenotype. We observed a concomitant downregulation of the Treg genes FOXP3 and IKZF2 (HELIOS) (Fig. 5E) , and an upregulation of CTLA4 (Fig. 5A) (Fig. 3B,C (Fig. 6A,B) . Notably, IL-6R hi TIGIT − mTregs were also found to produce very high levels of the antiinflammatory cytokine IL-10 ( Fig. 6A,B) . Importantly, the expression of genes that were specifically upregulated in IL-6R hi TIGIT − mTregs were found to be remarkably similar to a set of signature genes that were uniquely expressed in a population of mouse lamina propria Tregs [56] . This set of genes included the expression of signature genes such as CTLA4, LAG3, CCR2, CCR5, IRF4, MAF and IKZF3 (AIOLOS) ex vivo ( Table 2 in Ref. [45] ), and the expression of IL10 and GZMB upon in vitro stimulation ( Fig. 6A,B) , whilst expressing lower levels of the Treg genes IKZF2 (HELIOS) and TNFRSF9 (CD137) (Fig. 6C) . In addition to cytokine production, in vitro stimulation also induced the expression of IL1R1 and IL23R on IL-6R hi TIGIT − mTregs (Fig. 6D) , suggesting an increased sensitivity to IL-1β and IL-23 signalling.
To investigate the functional heterogeneity within IL-6R hi TIGIT − mTregs, we then examined the production of IL-17 and IL-10 at the single-cell level by flow cytometry following in vitro activation. Given that IL-6R is shed upon in vitro activation, we could not use it to delineate IL-6R hi TIGIT − mTregs, but instead focused on the total TIGIT − mTreg population. Consistent with previous observations [57, 58] , we showed that the HELIOS − fraction of TIGIT − mTregs contained the vast majority of cytokine-producing Tregs (Fig. 7A,B) . In contrast, there was a much higher level of heterogeneity among the FOXP3-defined subsets, with both FOXP3 + and FOXP3 − Tregs showing the ability to produce IL-10 and IL-17 (Fig. 7A,B) . We found that the majority of IL-10 and IL-17 producing cells were distinct (Fig. 7C) Transcriptional analysis also identified the increased expression of two additional chemokine receptors, CCR2 and CCR5, among the top differentially expressed genes in ex vivo isolated IL-6R hi TIGIT − mTregs (Table 2 in Ref. [45] ). To investigate the gut-homing capacity of IL-6R hi TIGIT − mTregs, we also assessed the expression of integrins α4
and β7 associated with migration to the colon, and the small intestine homing marker CCR9 (Fig. 10A ,B in Ref. [45] ). Expression of both the α4 monomer and the α4β7 heterodimer as well as CCR9, were increased on IL-6R hi TIGIT − mTregs (Fig. 10C in Ref. [45] ), demonstrating that a portion of IL-6R hi TIGIT − mTregs possess the capacity to migrate to the gut.
Discussion
The critical role of Tregs in mediating protection from autoimmunity has led to many studies over the past decades, which have vastly contributed to our knowledge about this immune subset, and to the development of therapeutic strategies targeting Tregs. However, with the development of novel genomics [46] and proteomics tools [62] , it is becoming apparent that there is phenotypic and functional heterogeneity among Tregs, which could lead to unexpected outcomes in clinical trials targeting Tregs in transplantation, tumour therapy and in autoimmune diseases.
In the present study we performed in-depth immunophenotyping of the expression of IL-6R on the human CD4 + CD127 low CD25 + T cell compartment ex vivo. Although IL-6R has been shown to be expressed by human Tregs [35, 63] , there is limited data describing its expression on different Treg subsets, and there has been no attempt to characterise the function of Tregs stratified by IL-6R expression. This is due to a combination of factors, namely the limited range of expression of IL-6R on human T cells, the large genetically-regulated inter-individual variation in expression levels [38] , the high sensitivity of IL-6R to shedding in CD25 and CTLA-4 (C) were assessed by flow cytometry in freshly isolated PBMCs from 33 healthy donors. P values were calculated using a two-tailed paired non-parametric Wilcoxon signed rank test.
and anti-inflammatory cytokines, upon in vitro stimulation (summarised in Table 1 ). Although we note that a population of Th17 Tregs has been previously described in humans [19] [20] [21] [22] , our data refines the characterisation of this subset, and reveals a remarkably consistent Th17 transcriptional profile and the capacity to produce a wide range of cytokines, most notably Th17-type cytokines, upon in vitro stimulation. A key finding was the observation that IL-6R within this compartment containing a significant fraction of activated effector Tregs, which likely mediate their suppression in part by IL-10 production [65] and CTLA-4 binding to the co-stimulatory molecules CD80 and CD86 [66, 67] . Furthermore, the elevated expression of CD25 compared to memory Teff cells, combined with the high sensitivity to IL-2 in vivo suggests that IL-6R hi TIGIT − mTregs are also able to mediate their suppression mechanism through IL-2 consumption [65] . These results are consistent with a previous study, characterising a subset of HELIOS − mTregs marked by the expression of the IL-1R and the transcription factor AIOLOS in humans, which were found to be more suppressive than conventional HELIOS + Tregs ex vivo [58] . In that study addition of exogenous IL-1β abrogated their suppressive capacity, through a mechanism dependent on the expression of the IL-1R [58] . Furthermore, another study has described a subset of FOXP3 + Tregs marked by the expression of CD161 with high in vitro suppressive capacity [68] . Similarly to the IL-6R hi TIGIT − mTregs described here, From an evolutionary perspective, there is evidence pointing to a common developmental pathway in the differentiation of both induced-Treg and Th17 lineages [27] , suggesting that Th17 Tregs could play an important role in the regulation of the immune responses and commensal bacteria composition in the gut [72] . This is consistent with the recent data showing that the composition of intestinal bacterial commensals is critical in regulating the frequency of a highly suppressive subset of RORγt + Tregs in mice [23, 24] , which are thought to regulate the interplay between commensal and pathogenic bacteria and the host immune system in the gut, while preventing chronic inflammation. Furthermore, another recent study in mice has shown that RORγt Our findings suggest that a similar gut-resident T cell subset exists in humans [73] , which is mobilised and expanded by IL-2 treatment and consequently becomes more detectable in the blood. In agreement with this hypothesis, IL-6R hi TIGIT − mTregs displayed a remarkably similar transcriptional profile with a population of Tregs resident in the mucosal tissues [56] , which strongly supports that IL-6R hi TIGIT − mTrsgs are located primarily in the intestine and mesenteric lymph nodes. In agreement with this hypothesis, IL-6R hi TIGIT − mTregs displayed a chemokine receptor profile consistent with a tissue-homing T cell subset, including the elevated expression of markers such as CCR2, CCR4, CCR5 and CCR6 and the adhesion marker CD15s, as well as the specific upregulation of the prototypical small intestine (CCR9) and colon (α4β7) homing receptors. These data demonstrate the tissue-homing properties of IL-6R hi TIGIT − mTregs, and their capacity to migrate to the gut, therefore supporting their potential intestinal nature, which is similar to their murine intestinal RORγt + FOXP3 + Treg analogues. Although the expansion of Tregs in circulation in response to IL-2 is not restricted to the IL-6R hi TIGIT − subset, we hypothesise that this subset could be particularly relevant for regulating Th17 responses, and expansion and trafficking in response to IL-2 signalling by IL-6R hi TIGIT − cells suggest an important role in the regulation of tissue inflammation and autoimmune reactions. One possibility that has been suggested in a mouse model is that IL-10 production by FOXP3 + Tregs is key to promote equilibrium with proinflammatory IL-17-producing RORγt + Th17 effector cells [74] . Our observation that IL-10 is expressed at high levels by IL-6R hi TIGIT − mTregs, suggests that they represent a major IL-10-producing Treg subset in humans, and play a critical role in the regulation of the IL-17-mediated immune responses at the sites of infection, which is key to maintain the homeostasis between commensal bacteria and invading pathogens at mucosal barrier surfaces. In the context of human autoimmune disease, IL-17-producing FOXP3 + Tregs with in vitro suppressive capacity have been shown to be recruited to the intestinal mucosa in active Crohn's disease patients [75] , to the inflamed joints of juvenile idiopathic arthritis (JIA) patients [68] and to peripheral blood of rheumatoid arthritis patients [76] . In addition, in psoriasis patients, IL-6R-expressing Tregs have been previously shown to be recruited to the inflamed skin, where they co-localise with the pathogenic IL-17 producing Th17 effector cells [35] . These observations are consistent with the recruitment of activated Th17-signature positive Tregs with suppressive function to the sites of infection to prevent or limit Th17 effector tissue damage. An intriguing question that remains to be addressed is the potential effect of prolonged exposure to pro-inflammatory signals on the differentiation and function of these RORγt + FOXP3 + Tregs, particularly in the setting of chronic inflammation. We have shown that mTregs can signal through the IL-6R by activating pSTAT3, and have previously demonstrated that elevated expression of IL-6R on CD4 + T cells translates to increased IL-6 signalling [38] . Furthermore, IL-6 is known to relieve the FOXP3-mediated suppression of RORγt [30] , leading to the disruption of the balance of RORγt and FOXP3 expression in IL-6R hi TIGIT − mTregs, and to the concomitant instability of FOXP3 expression in these cells. We therefore hypothesise that in genetically-susceptible individuals at the IL6R locus, the increased IL-6 signalling potential increases the sensitivity of IL-6R hi TIGIT − mTregs to IL-6, resulting in the loss of regulatory potential and to the trans-differentiation into pathogenic IL-17-producing ex-Tregs [77] [78] [79] . In summary, our findings identify a subset of HELIOS − FOXP3 + Tregs, which can be detected in vivo based on the expression of two surface markers, IL-6R and TIGIT, and show that subcutaneously administered IL-2 can promote the expansion and trafficking of these cell subsets into circulation. Although the frequency of these cells is usually low in peripheral blood, ranging from 0.4% to 1.4% of total circulating CD45RA − memory CD4 + T cells, their frequency is expanded with single doses of IL-2 of around 400,000 IU/m 2 [15] . Moreover, the strong in vitro suppressive capacity of IL-6R hi TIGIT − mTregs coupled with their potential to produce a diversity of pro-and anti-inflammatory cytokines, suggests that their frequency should be carefully monitored, particularly in autoinflammatory diseases, in which chronic inflammation could promote the migration of these cells from the gut to inflamed tissues. As clinical studies aiming to expand Tregs become more prevalent, another important application of these markers will be to assess preferential expansion of specific Treg and additional CD127 low CD25 + Teff subsets, and inform on disease-specific dosing and patient selection, especially in conditions where IL-17 is a cause of tissue damage [80] . Our findings also suggest a biological mechanism underpinning the genetic association of the IL6R with human inflammatory diseases, whereby in genetically susceptible individuals, increased IL-6 signalling could impair the regulatory function of a tissue-resident Treg subset with potent suppressive potential. These data provide a rationale for specific targeting of this molecular pathway in diseases genetically associated with the IL6R locus, rather than non-specific blockade of IL-6 signalling which brings with it an increased risk of infection that might not be acceptable in the context of T1D in children. 
